VBI-1901: SNO Phase 2a Data & Clinical Update
November 19, 2020 | Video
Jeff Baxter and David E. Anderson, Ph.D., discuss updated Phase 2a (Part B) data of VBI-1901 in recurrent GBM patients, as presented at SNO 2020.
November 19, 2020 | Video
Jeff Baxter and David E. Anderson, Ph.D., discuss updated Phase 2a (Part B) data of VBI-1901 in recurrent GBM patients, as presented at SNO 2020.
Adam Finn, M.D., Ph.D., discusses Data from the Sci-B-Vac® Phase 3 program at EASL.
VBI discusses preclinical coronavirus program data and selection of clinical candidates with potential as one-dose vaccines.
David E. Anderson, Ph.D., discusses updated Part B data from the VBI’s ongoing Phase 1/2a study of VBI-1901.
In preclinical studies, VBI demonstrated that its vaccine candidate stimulated immune responses critical to efficacious anti-tumor immunity.
Sci-B-Vac™ is a licensed third-generation hepatitis B vaccine that has demonstrated safety and efficacy in over 300,000 patients. Sci-B-Vac™ is currently approved for use in Israel and in 14 other countries.
Medulloblastoma is the most common malignant primary brain tumor in children.
Glioblastoma is among the most common and aggressive malignant primary brain tumors in humans. In the U.S. alone, 12,000 new cases are diagnosed each year. The current standard of care for GBM is surgical resection, followed by radiation and chemotherapy. Even with aggressive treatment, GBM progresses rapidly and is exceptionally lethal, with median patient survival of less than sixteen months.
Hepatitis B is a disease of the liver caused by the hepatitis B virus (“HBV”) characterized by inflammation, injury, and even cell death.
VBI’s eVLP Platform allows for the design of enveloped (“e”) virus-like particle (“VLP”) vaccines.
